{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:37:40Z","timestamp":1776058660628,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00210-024-03557-y","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:22:55Z","timestamp":1730712175000},"page":"4503-4511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sarecycline for moderate to severe acne: a promising narrow-spectrum antibacterial drug"],"prefix":"10.1007","volume":"398","author":[{"given":"Amr","family":"Elrosasy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8165-9470","authenticated-orcid":false,"given":"Mohamed","family":"Abo Zeid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esraa M.","family":"AlEdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira A.","family":"Aboali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya M.","family":"Fayoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kareem","family":"Ibraheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha Abdullah","family":"Alwaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Selim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Hamdy","family":"Zabady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"3557_CR1","doi-asserted-by":"publisher","unstructured":"Moore AY, Hurley K, Moore SA, et al (2023) Effect of sarecycline on the acne symptom and impact scale and concerns in moderate-to-severe truncal acne in open-label pilot study. Antibiotics (Basel) 12:. https:\/\/doi.org\/10.3390\/antibiotics12010094","DOI":"10.3390\/antibiotics12010094"},{"key":"3557_CR2","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2217\/fmb-2019-0199","volume":"14","author":"AY Moore","year":"2019","unstructured":"Moore AY, Charles JEM, Moore S (2019) Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol 14:1235\u20131242. https:\/\/doi.org\/10.2217\/fmb-2019-0199","journal-title":"Future Microbiol"},{"key":"3557_CR3","first-page":"E53","volume":"12","author":"DM Pariser","year":"2019","unstructured":"Pariser DM, Green LJ, Lain EL et al (2019) Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-label study and a phase I phototoxicity study. J Clin Aesthet Dermatol 12:E53\u2013E62","journal-title":"J Clin Aesthet Dermatol"},{"key":"3557_CR4","first-page":"333","volume":"17","author":"JJ Leyden","year":"2018","unstructured":"Leyden JJ, Sniukiene V, Berk DR, Kaoukhov A (2018) Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study. J Drugs Dermatol 17:333\u2013338","journal-title":"J Drugs Dermatol"},{"key":"3557_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jaad.2023.04.075","volume":"89","author":"JC Harper","year":"2023","unstructured":"Harper JC, Armstrong A, Fried RG et al (2023) Patient-reported outcomes with sarecycline treatment for acne vulgaris: pooled analysis of phase 3 clinical studies. J Am Acad Dermatol 89:832\u2013834. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.075","journal-title":"J Am Acad Dermatol"},{"key":"3557_CR6","doi-asserted-by":"publisher","unstructured":"Moura IB, Grada A, Spittal W, et al (2022) Profiling the effects of systemic antibiotics for acne, including the narrow-spectrum antibiotic sarecycline, on the human gut microbiota. Front Microbiol 13:. https:\/\/doi.org\/10.3389\/fmicb.2022.901911","DOI":"10.3389\/fmicb.2022.901911"},{"key":"3557_CR7","doi-asserted-by":"publisher","unstructured":"Zhanel G, Critchley I, Lin L-Y, Alvandi N (2019) Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother 63:. https:\/\/doi.org\/10.1128\/AAC.01297-18","DOI":"10.1128\/AAC.01297-18"},{"key":"3557_CR8","unstructured":"(2019) Sarecycline (Seysara) - another oral tetracycline for acne. Med Lett Drugs Ther 61:43\u201344"},{"key":"3557_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1060028019873111","volume":"54","author":"W Haidari","year":"2020","unstructured":"Haidari W, Bruinsma R, Cardenas-de la Garza JA, Feldman SR (2020) Sarecycline review. Ann Pharmacother 54:164\u2013170. https:\/\/doi.org\/10.1177\/1060028019873111","journal-title":"Ann Pharmacother"},{"key":"3557_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1358\/dot.2019.55.10.3045040","volume":"55","author":"G Kaul","year":"2019","unstructured":"Kaul G, Saxena D, Dasgupta A, Chopra S (2019) Sarecycline hydrochloride for the treatment of acne vulgaris. Drugs Today (Barc) 55:615\u2013625. https:\/\/doi.org\/10.1358\/dot.2019.55.10.3045040","journal-title":"Drugs Today (Barc)"},{"key":"3557_CR11","first-page":"245","volume":"102","author":"J Rupert","year":"2020","unstructured":"Rupert J, Hughes P (2020) Sarecycline (Seysara) for the treatment of acne. Am Fam Physician 102:245\u2013246","journal-title":"Am Fam Physician"},{"key":"3557_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14656566.2020.1813279","volume":"22","author":"V Duarte","year":"2021","unstructured":"Duarte V, de Sousa IC (2021) An overview of sarecycline for the treatment of moderate-to-severe acne vulgaris. Expert Opin Pharmacother 22:145\u2013154. https:\/\/doi.org\/10.1080\/14656566.2020.1813279","journal-title":"Expert Opin Pharmacother"},{"key":"3557_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103\u2013112. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.02.003","journal-title":"J Clin Epidemiol"},{"key":"3557_CR14","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane handbook for systematic reviews of interventions.\nhttps:\/\/doi.org\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"3557_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"3557_CR16","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898\u2013l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"3557_CR17","first-page":"987","volume":"17","author":"A Moore","year":"2018","unstructured":"Moore A, Green LJ, Bruce S et al (2018) Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol 17:987\u2013996","journal-title":"J Drugs Dermatol"},{"key":"3557_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/antibiotics10040439","volume":"10","author":"CG Bunick","year":"2021","unstructured":"Bunick CG, Keri J, Tanaka SK et al (2021) Antibacterial mechanisms and efficacy of sarecycline in animal models of infection and inflammation. Antibiotics 10:439. https:\/\/doi.org\/10.3390\/antibiotics10040439","journal-title":"Antibiotics"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03557-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:02:27Z","timestamp":1744164147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03557-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3557"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03557-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}